Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease

Canadian Journal of Cardiology

Volumn 22, Issue 10, 2006, Pages 863-868

  Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Hypercholesterolemia; Lipid lowering drugs; Selective inhibitors of cholesterol absorption

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DEXTROMETHORPHAN; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIDAZOLAM; PHYTOSTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TOLBUTAMIDE; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIET; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DYSLIPIDEMIA; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SMOKING CESSATION; WEIGHT REDUCTION; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; TREATMENT OUTCOME;

EID: 33749066957     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70305-1     Document Type: Review

References (37)

1. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
2. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia and prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169:921-4.
3. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group Recommendations. Am J Cardiol 2005;96:556-63.
4. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study-Observational (CALIPSO) study. Can J Cardiol 2005;21:1187-93.
5. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
6. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. New Engl J Med 2005;352:1425-35.
7. Genest J, Pedersen TR. Prevention of cardiovascular ischemic disease: High-risk and secondary prevention. Circulation 2003;107:2059-65.
8. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
9. Moghadasian MH, Frohlich JJ, Saleem M, Hong JM, Qayumi K, Scudamore CH. Surgical management of dyslipidemias: Clinical and experimental evidence. J Invest Surg 2001;14:71-8.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.
12. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvaststin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7-22.
14. Scott R, Best J, Forder P, et al; FIELD Study Investigators. Fenofibrate Intervention and Event Lowering in Diabetics (FIELD) study: Baseline characteristics and short-term effects of fenofibrate. Cardiovasc Diabetol 2005;4:13.
15. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
16. Catapano A. Ezetimibe: A selective inhibitor of cholesterol absorption. Eur Heart J 2001;3(Suppl E):E6-10.
17. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134:409-17.
18. Salen G, von Bergmann K, Lutjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109:966-71.
19. Knopp RH, Gitter H, Truitt T, et al; Ezetimibe Study Group. Effect of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patient with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
20. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-7.
21. Evans M, Roberts A, Rees A. The future direction of cholesterol-lowering therapy. Curr Opin Lipidol 2002;13:663-9.
22. Brown W. Novel approaches to lipid lowering. What is on the horizon? Am J Cardiol 2001;87(5A):23B-27B.
23. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8.
24. Kastelein J, van Dam MJ. A new role for combination therapy in lipid management. Br J Cardiol 2001;8:639-53.
25. Simard C, Turgeon J. The pharmacokinetics of eztemibe. Can J Clin Pharmacol 2003;10(Suppl A):13A-20A.
26. Excecutive Summary of The Thrid Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
27. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
28. Dujovne CA, Ettinger MP, McNeer JF, et al; Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7.
29. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.
30. Feldman T, Koren M, Insull W, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-6.
31. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94.
32. Goldberg A, Sapre A, Liu J, et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-9.
33. Simons L, Tonkon, Masana L, et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20:1437-45.
34. Ballantyne CM, Houri J, Notabartolo A, et al; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.
35. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95.
36. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atheroscler 2005;179:361-7.
37. Pedersen TR, Faergeman O, Kastelein JJ, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: A randomized controlled trial. JAMA 2005;294:2437-45. (Erratum in 2005;294:3092).